Accelagen is a rapidly expanding player in the biotechnology and healthcare industries. Founded in 2007, the company specializes in gene-to-protein services, utilizing advanced technologies such as Baculovirus Expression Vector System (BEVS), E. coli expression, mammalian expression, Wave Bioreactors, Cell Factory, and AKTA chromatography systems. This integrated platform enables Accelagen to deliver high-quality proteins, while significantly expediting the processes from gene to protein. Despite not having specific data on their headquarter or recent investment activities, Accelagen's innovative approach and strong foothold in the biotech and healthcare sectors make it an intriguing prospect for venture capitalists seeking to capitalize on the burgeoning demand for advanced protein production technologies.
There is no investment information
No recent news or press coverage available for Accelagen.
We care about your data, and we'd love to use cookies make your experience better.